Advertisement

Topics

FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

01:10 EDT 31 Oct 2018 | Drugs.com

Holzkirchen, Germany, October 31, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted...

Original Article: FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...